登录 | 注册    关注公众号  
微信公众号
搜索
 >  Antibody>CD28 >GMP-MC2824

GMP Monoclonal Anti-Human CD28 Antibody DMF

PG version CD8-M120b is now available for seamless transition.

优势特色(Features)

  1. Designed under ISO 9001:2015 and ISO 13485:2016
  2. Manufactured and QC tested under a GMP compliance factory
  3. FDA DMF filed
  4. Animal-Free materials
  5. Batch-to-batch consistency
  6. Stringent quality control tests

抗体来源(Source)

HEK293 cells-expressed human GMP Monoclonal Anti-Human CD28 Antibody.

亚型(Isotype)

Mouse IgG1 | Mouse Kappa

偶联(Conjugate)

Unconjugated

特异性(Specificity)

This product is a specific antibody specifically reacts with CD28.

内毒素(Endotoxin)

Less than 2 EU/mg by the LAL method.

蛋白A残留(Protein A)

<5 ppm of protein tested by ELISA.

宿主蛋白残留(Host Cell Protein)

<0.5 ng/μg of protein tested by ELISA.

宿主核酸残留(Host Cell DNA)

<0.02 ng/μg of protein tested by qPCR.

纯度(Purity)

>95% as determined by SDS-PAGE.

>95% as determined by SEC-HPLC.

无菌(Sterility)

The sterility testing was performed by membrane filtration method described in USP<71> and Ph. Eur. 2.6.1.

支原体(Mycoplasma)

Negative.

制剂(Formulation)

Supplied as 0.2 μm filtered solution in PBS, polysorbate 80, pH7.4 with protectants.

Contact us for customized product form or formulation.

运输(Shipping)

This product is supplied and shipped with dry ice, please inquire the shipping cost.

存储(Storage)

For long term storage, the product should be stored at liquid state at -70°C.

This product is stable after storage at:

  1. 2-8°C for 12 months under sterile condition;
  2. -70°C for 5 years.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

CD28 SDS-PAGE

GMP Monoclonal Anti-Human CD28 Antibody on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-HPLC

CD28 SEC-HPLC

The purity of GMP Monoclonal Anti-Human CD28 Antibody (Cat. No. GMP-MC2824) was greater than 95% as determined by SEC-HPLC.

 

活性(Bioactivity)-CELL BASE

CD28 CELL

GMP Monoclonal Anti-Human CD28 Antibody (Cat. No. GMP-MC2824) stimulates secretion of IL-2 by PBMC stimulated with 4ng/mL GMP Monoclonal Anti-Human CD3 Antibody (OKT3). The typically EC50 for this effect is 1.382 ng/mL (QC tested).

Protocol

CD28 CELL

The activity of GMP Monoclonal Anti-Human CD28 Antibody (Cat. No. GMP-MC2824) was higher than other competing products.

 

稳定性(Stability)

CD28 STABILITY

The Cell based assay shows that GMP Monoclonal Anti-Human CD28 Antibody (Cat. No. GMP-MC2824) is stable at 37°C for 7 days.

CD28 STABILITY

The Cell based assay shows that GMP Monoclonal Anti-Human CD28 Antibody (Cat. No. GMP-MC2824) is stable after freezing and thawing 3 times.

CD28 STABILITY

The Cell based assay shows batch-to-batch consistency between Acro's GMP and PG CD28 Antibody.

MANUFACTURING SPECIFICATIONS

ACROBiosystems GMP grade products are produced under a quality management system and in compliance with relevant guidelines: Ph. Eur General Chapter 5.2.12 Raw materials of biological origin for the production of cell-based and gene therapy medicinal products; USP <92> Growth Factors and Cytokines Used in Cell Therapy Manufacturing; USP <1043> Ancillary Materials for Cell, Gene, and Tissue-Engineered Products; ISO/TS 20399-1:2018, Biotechnology - Ancillary Materials Present During the Production of Cellular Therapeutic Products.


ACROBiosystems Quality Management System Contents:

  1. Designed under ISO 9001:2015 and ISO 13485:2016, Manufactured and QC tested under a GMP compliance factory.
  2. Animal-Free materials
  3. Materials purchased from the approved suppliers by QA
  4. ISO 5 clean rooms and automatic filling equipment
  5. Qualified personnel
  6. Quality-related documents review and approve by QA
  7. Fully batch production and control records
  8. Equipment maintenance and calibration
  9. Validation of analytical procedures
  10. Stability studies conducted
  11. Comprehensive regulatory support files

Request For Regulatory Support Files(RSF)   Request For DMF


ACROBiosystems provide rigorous quality control tests (fully validated equipment, processes and test methods) on our GMP grade products to ensure that they meet stringent standards in terms of purity, safety, activity and inter-batch stability, and each bulk QC lot mainly contains the following specific information:

  1. SDS-PAGE
  2. Protein content
  3. Endotoxin level
  4. Residual Host Cell DNA content
  5. Residual Host Cell Protein content
  6. Biological activity analysis
  7. Microbial testing
  8. Mycoplasma testing
  9. In vitro virus assay
  10. Batch-to-batch consistency


DISCLAIMER

ACROBiosystems GMP grade products are designed for research, manufacturing use or ex vivo use. CAUTION: Not intended for direct human use.

TERMS AND CONDITIONS

All products are warranted to meet ACROBiosystems Inc.’s (“ACRO”) published specifications when used under normal laboratory conditions.


ACRO DOES NOT MAKE ANY OTHER WARRANTY OR REPRESENTATION WHATSOEVER, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO ITS PRODUCTS. IN PARTICULAR, ACRO DOES NOT MAKE ANY WARRANTY OF SUITABILITY, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE.

NOT WITH STANDING ANY OTHER PROVISIONS OF THESE TERMS AND/OR ANY OTHER AGREEMENT BETWEEN ACRO AND PURCHASER FOR THE PURCHASE OF THE PRODUCTS, ACRO’S TOTAL LIABILITY TO PURCHASER ARISING FROM OR IN RELATION TO THESE TERMS, AN AGREEMENT BETWEEN THE PARTIES OR THE PRODUCTS, WHETHER ARISING IN CONTRACT, TORT OR OTHERWISE SHALL BE LIMITED TO THE TOTAL AMOUNT PAID BY PURCHASER TO ACRO FOR THE RELEVANT PRODUCTS. IN NO EVENT WILL ACRO BE LIABLE FOR THE COST OF PROCUREMENT OF SUBSTITUTE GOODS.

END USER TERMS OF USE OF PRODUCT

The following terms are offered to you upon your acceptance of these End User Terms of Use of Product. By using this product, you indicate your acknowledgment and agreement to these End User Terms of Use of Product. If you do not agree to be bound by and comply with all of the provisions of these End User Terms of Use of Product, you should contact your supplier of the product and make arrangements to return the product.

The End User is aware that ACROBiosystems Inc. and its affiliate (“ACRO”) sell GMP grade products designed for research, manufacturing use or ex vivo use and not intended for human in vivo applications. The End User further agrees, as a condition of the sales of ACRO’s GMP grade products that: a) the End User will not use this GMP grade product in any procedure wherein the product may be directly or indirectly administered to humans, unless the End User has obtained, or prior to their use will have obtained, an Investigational New Drug (IND) exemption from the FDA and will use the product only in accordance with the protocols of such IND and of the Institutional Review Board overseeing the proposed research, or b) the End User will use the products outside of the United States in accordance with the protocols of research approved by the applicable review board or authorized ethics committee and regulatory agencies to which the End User is subject to in their territory.

 
评论(0)
 
ACRO质量管理体系
 
 

背景(Background)

T-cell-specific surface glycoprotein CD28 is also known as TP44, is a single-pass type I membrane protein which contains one Ig-like V-type (immunoglobulin-like) domain. is one of the molecules expressed on T cells that provide co-stimulatory signals, which are required for T cell activation. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2). When activated by Toll-like receptor ligands, the CD80 expression is upregulated in antigen presenting cells (APCs). The CD86 expression on antigen presenting cells is constitutive. CD28 is the only B7 receptor constitutively expressed on naive T cells.

 

前沿进展

Plasma proteomic biomarkers predict therapeutic responses in advanced biliary tract cancer patients receiving Camrelizumab plus the GEMOX treatment
Cui, Zheng, Xu et al
NPJ Precis Oncol (2025) 9 (1), 102
Abstract: Biliary tract cancer (BTC) has greatly influenced patient survival for years. Nowadays, immunotherapy represents a promising breakthrough and proteomics is one of powerful technologies in biomarker research. We collected plasma and tissue samples from 37 patients with advanced BTC and 92 proteins were analyzed by proximity extension assay (PEA). Through linear mixed effect models, compared to partial response (PR) group, 8 proteins, IL7, ANGPT2, IL15, HO-1, CXCL1, CXCL5, IL33, and VEGFA, exhibited significantly higher expression in stable disease and progressive disease (SD_PD) group in response-effect analysis. It was also revealed that a subset of proteins increased over time, including PDCD1, TNFRSF4, DCN, CRTAM, VEGFR-2 and ADA in PR group and PDCD1, IL10, ADA, CD28, and PTN in SD_PD group. In interaction-effect analysis, HO-1, ANGPT2, IL15 were three significant differentially expressed proteins (DEPs). Receiver operating characteristic (ROC) analysis further demonstrated that HO-1, ANGPT2, IL15 showed high accuracy in patients with immune checkpoint blockade (ICB) treatment plus chemotherapy (AUC = 0.74). In addition, based on the obtained plasma and tissue samples, two nomogram models were constructed for predicting the prognosis of BTC by genome combined with proteomics. Collectively meaningful proteomic biomarkers are beneficial to evaluate the efficacy of immunotherapy, and these discovered biomarkers may be included in the scope of treatments' evaluation and improvement in future study.© 2025. The Author(s).
Potency-optimized CD28-activating bispecific antibody for the targeted treatment of Nectin-4 positive cancers
Kaur, Rüger, Chen et al
J Immunother Cancer (2025) 13 (4)
Abstract: T-cell costimulation is crucial for an effective and sustained antitumor immune response, and inadequate expression of costimulatory ligands within tumors can impair T-cell function. Bispecific antibodies (bsAbs) targeting a tumor-associated antigen and the T-cell costimulatory receptor CD28 represent a novel class of immune-stimulatory therapeutics designed to enhance antitumor immune responses by selectively delivering T-cell costimulation directly to the tumor microenvironment. This approach holds the potential to improve the survival, proliferation, and cytotoxic function of antitumor T cells while minimizing the risk of systemic immune activation. Urothelial cancer (UC) is associated with significant morbidity and mortality worldwide, particularly in advanced disease settings. Nectin-4, a membrane protein highly expressed in UC with limited expression in healthy tissues, presents a compelling target for therapeutic intervention.Using our proprietary high-throughput antibody discovery pipeline, we identified a panel of novel antibodies with a range of affinities for CD28 and Nectin-4 and successfully engineered them as bsAbs. We tested the T-cell costimulatory function of these molecules in vitro using primary human T cells and human cancer cell lines. Based on these results, we selected a clinical candidate which we assessed in a syngeneic mouse tumor model system and investigated tolerability and pharmacokinetics (PK) in non-human primates (NHP).Our in vitro studies demonstrated that these bsAbs effectively enhance T-cell activation and cytotoxicity against Nectin-4 positive tumor cells in the presence of T-cell receptor engagement. The bsAb panel exhibited a range of potencies, enabling the selection of a clinical candidate, termed RNDO-564, that maximized antitumor efficacy as well as the likelihood of a broad therapeutic window. Tumor-bearing syngeneic mouse models confirmed the in vivo efficacy of RNDO-564, demonstrating significant tumor regression both as a single agent and in combination with an immune checkpoint inhibitor. We observed favorable PK and tolerability profiles in NHP assessments.Our study reports the first CD28 bsAb targeting Nectin-4 and highlights the potential of CD28 × Nectin-4 bsAbs as a new immunotherapeutic modality. The findings support the clinical development of RNDO-564 in patients with locally advanced and metastatic UC and other Nectin-4 positive malignancies.© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.
Advances in CAR optimization strategies based on CD28
Li, Zhou, Wang et al
Front Immunol (2025) 16, 1548772
Abstract: Chimeric antigen receptor (CAR)-T cell therapy, which utilizes genetic engineering techniques to modify T-cells to achieve specific targeting of cancer cells, has made significant breakthroughs in cancer treatment in recent years. All marketed CAR-T products are second-generation CAR-T cells containing co-stimulatory structural domains, and co-stimulatory molecules are critical for CAR-T cell activation and function. Although CD28-based co-stimulatory molecules have demonstrated potent cytotoxicity in the clinical application of CAR-T cells, they still suffer from high post-treatment relapse rates, poor efficacy durability, and accompanying severe adverse reactions. In recent years, researchers have achieved specific results in enhancing the anti-tumor function of CD28 by mutating its signaling motifs, combining the co-stimulatory structural domains, and modifying other CAR components besides co-stimulation. This paper reviewed the characteristics and roles of CD28 in CAR-T cell-mediated anti-tumor signaling and activation. We explored potential strategies to enhance CAR-T cell efficacy and reduce side effects by optimizing CD28 motifs and CAR structures, aiming to provide a theoretical basis for further clinical CAR-T cell therapy development.Copyright © 2025 Li, Zhou, Wang, Qu, Zhao, Wang, Hou, Guan, Liu, Zheng and Shi.
The Structural Biology of T-Cell Antigen Detection at Close Contacts
Lui, Ferreira Fernandes, Vuong et al
Immunol Rev (2025) 331 (1), e70014
Abstract: T cells physically interrogate their targets using tiny membrane protrusions called microvilli, forming junctions ~400 nm in diameter and ~ 15 nm deep, referred to as "close contacts". These contacts, which are stabilized by the binding of the small adhesion protein CD2 to its ligand, CD58 and locally exclude large proteins such as the phosphatase CD45, are the sites of antigen recognition by the T-cell receptor (TCR) and very early signaling by T cells. With our collaborators, we have characterized the molecular structures of several of the key proteins mediating these early events: i.e., CD2 and its ligands, CD45, the αβ- and γδ-TCRs, and the accessory proteins CD28, CTLA-4, and PD-1. Here, we review our structural work and the insights it offers into the early events underpinning T-cell responsiveness that take place in the confined space of the close contact. We reflect on the crucial roles that the structural organization and dimensions of these proteins are likely to have in determining the sequence of events leading to antigen recognition at close contacts and consider the general implications of the structural work for explanations of how immune receptor signaling is initiated.© 2025 The Author(s). Immunological Reviews published by John Wiley & Sons Ltd.
Showing 1-4 of 13850 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
法规支持文档(RSF)
一级-产品资质文档(免费)
二级-独特的质量和全性文档(付费)
点击咨询和申请
CD28靶点信息
英文全称:T-cell-specific surface glycoprotein CD28
中文全称:T细胞特异性表面糖蛋白CD28
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:25详情
最高研发阶段:临床二期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定